Kadence Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Series A1

  • Latest Deal Amount
  • $17M

  • Investors
  • 23

Kadence General Information

Description

Developer of a small-molecule therapeutic designed to address significant unmet needs in sexual and mental well-being. The company offers a clinical-stage treatment for premature ejaculation, enabling men experiencing challenges with sexual performance, mental health, and relationship well-being to access the first FDA-approved therapeutic option.

Contact Information

Website
www.kadencebio.com
Formerly Known As
Kanna Health
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1st Floor One Suffolk Way
  • Sevenoaks TN13 1YL
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 1st Floor One Suffolk Way
  • Sevenoaks TN13 1YL
  • England, United Kingdom

Kadence Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kadence Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC (Series A1) 07-Aug-2026 $17M Completed Clinical Trials - Phase 2
4. Accelerator/Incubator 01-Oct-2024 Completed Clinical Trials - Phase 1
3. Accelerator/Incubator 23-Sep-2024 Completed Clinical Trials - Phase 1
2. Accelerator/Incubator 13-Oct-2023 $6.16M Completed Pre-Clinical Trials
1. Seed Round 31-Oct-2021 $6.16M $6.16M Completed Startup
To view Kadence’s complete valuation and funding history, request access »

Kadence Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
B Ordinary
A1 Ordinary
To view Kadence’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Kadence Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a small-molecule therapeutic designed to address significant unmet needs in sexual and mental well-being. T
Drug Discovery
Sevenoaks, United Kingdom
4 As of 2026

Sevilla, Spain
 

Hod HaSharon, Israel
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kadence Competitors (2)

One of Kadence’s 2 competitors is MYHIXEL, a Venture Capital-Backed company based in Sevilla, Spain.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
MYHIXEL Venture Capital-Backed Sevilla, Spain
Virility Medical Venture Capital-Backed Hod HaSharon, Israel
You’re viewing 2 of 2 competitors. Get the full list »

Kadence Patents

  • 29

    Total Documents Applications and Grants

  • Total Patents Families

  • 4

    Granted

  • 20

    Pending

  • Expiring in next 12 mo

Kadence Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4598904-A1 Preparation of mesembrine Pending 07-Oct-2022
GB-202214772-D0 Preparation of mesembrine Pending 07-Oct-2022
GB-2623122-A Preparation of mesembrine Pending 07-Oct-2022
US-20260132108-A1 Preparation of mesembrine Pending 07-Oct-2022
WO-2024074831-A1 Preparation of mesembrine Inactive 07-Oct-2022 C07D209/12
To view Kadence’s complete patent history, request access »

Kadence Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kadence Investors (23)

Investor Name Investor Type Holding Investor Since Participating Rounds
Ayuh Ventures Venture Capital Minority
BC Growth Equity Angel Group Minority
Dhuna Ventures Venture Capital Minority
FJ Labs Venture Capital Minority
Vox Capital Venture Capital Minority
You’re viewing 5 of 23 investors. Get the full list »

Ready to get started?

Request a free trial

Kadence FAQs

  • When was Kadence founded?

    Kadence was founded in 2021.

  • Where is Kadence headquartered?

    Kadence is headquartered in Sevenoaks, United Kingdom.

  • What is the size of Kadence?

    Kadence has 4 total employees.

  • What industry is Kadence in?

    Kadence’s primary industry is Drug Discovery.

  • Is Kadence a private or public company?

    Kadence is a Private company.

  • What is Kadence’s current revenue?

    The current revenue for Kadence is .

  • How much funding has Kadence raised over time?

    Kadence has raised $23.3M.

  • Who are Kadence’s investors?

    Ayuh Ventures, BC Growth Equity, Dhuna Ventures, FJ Labs, and Vox Capital are 5 of 23 investors who have invested in Kadence.

  • Who are Kadence’s competitors?

    MYHIXEL and Virility Medical are competitors of Kadence.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process